![]() | |
Names | |
---|---|
IUPAC name
(2S)-2-Amino-4-(S-methylsulfonimidoyl)butanoic acid
| |
Other names
l-Methionine sulfoximine; MSO
| |
Identifiers | |
3D model (
JSmol)
|
|
1725509 | |
ChEBI | |
ChemSpider | |
ECHA InfoCard | 100.016.224 |
EC Number |
|
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C5H12N2O3S | |
Molar mass | 180.22 g·mol−1 |
Related compounds | |
Related compounds
|
Buthionine sulfoximine Glufosinate |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Methionine sulfoximine (MSO, also known as MetSox [1]) is an irreversible glutamine synthetase inhibitor. It is the sulfoximine derivative of methionine with convulsant effects. [2]
Methionine sulfoximine is composed of two different diastereomers, which are L-S-Methionine sulfoximine and L-R-Methionine sulfoximine. These affect the longevity of the model mouse for Lou Gehrig's disease. [3] Overproduction of glutamate results to excitotoxicity, which kills the cell. Since methionine sulfoximine inhibits glutamate production in the brain, it prevents excitotoxicity. Thus, increasing the longevity of the mice. [4]
MSO is phosphorylated by glutamine synthetase. The resulting product acts as a transition state analog that is unable to diffuse from the active site, thereby inhibiting the enzyme. [5]
![]() | |
Names | |
---|---|
IUPAC name
(2S)-2-Amino-4-(S-methylsulfonimidoyl)butanoic acid
| |
Other names
l-Methionine sulfoximine; MSO
| |
Identifiers | |
3D model (
JSmol)
|
|
1725509 | |
ChEBI | |
ChemSpider | |
ECHA InfoCard | 100.016.224 |
EC Number |
|
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C5H12N2O3S | |
Molar mass | 180.22 g·mol−1 |
Related compounds | |
Related compounds
|
Buthionine sulfoximine Glufosinate |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Methionine sulfoximine (MSO, also known as MetSox [1]) is an irreversible glutamine synthetase inhibitor. It is the sulfoximine derivative of methionine with convulsant effects. [2]
Methionine sulfoximine is composed of two different diastereomers, which are L-S-Methionine sulfoximine and L-R-Methionine sulfoximine. These affect the longevity of the model mouse for Lou Gehrig's disease. [3] Overproduction of glutamate results to excitotoxicity, which kills the cell. Since methionine sulfoximine inhibits glutamate production in the brain, it prevents excitotoxicity. Thus, increasing the longevity of the mice. [4]
MSO is phosphorylated by glutamine synthetase. The resulting product acts as a transition state analog that is unable to diffuse from the active site, thereby inhibiting the enzyme. [5]